24 January 2023 | Tuesday | News
Frédéric, a biologist by training (ENS, MBA from the College of Engineers), is a recognized leader, with more than 25 years of experience in the health sector. Prior to joining Genomic Vision, he was Managing Director of Ethera, a manufacturer of air quality analysis products. Prior to that, he was Chief Executive Officer of Platine Pharma Services SAS (a company that Bio Mérieux Group has since acquired), an analytical services company specializing in monitoring the immune response of patients in clinical trials (CRO), as well as TxCell, a biotechnology company developing cellular immunotherapies. At Genomic Vision, Frédéric will be in charge of managing all operational aspects of the company.
Frédéric Hammel, Director of Operations at Genomic Vision, said: " I am very pleased to join the dynamic team of Genomic Vision, which is committed to bringing excellence to its customers, especially in this momentum, where the robustness of the he technology opens up new application opportunities.»
Frédéric will be supported by the new Director of Human Resources, Claire Fleury, who has been involved in Human Resources for more than 20 years. With a Master's degree in Human and Social Sciences, completed with a Master's degree in Advanced Studies in Management, she will supervise the human resources of Genomic Vision.
Claire Fleury, Directorof Genomic Vision H umaines Resources, says: "Joining Genomic vision means having the conviction that anything is possible, that resources are where we look and undertake. I am delighted to support the company's teams: expert, dynamic and positive teams are part of the deployment of innovative projects in the service of health. »
Aaron Bensimon, Resident P CEOof Genomic Vision, said: "We are very pleased to welcome Claire and Frédéric to the Genomic Vision leadership team. They will help us build a strong business and provide exceptional genomic analysis solutions for our clients. Frédéric brings his knowledge in biotechnologyand his experience in the field of advanced therapies, a definite advantage for our teams. At the same time, we welcome Claire with great pleasure. It will play a critical role in supporting our workforce and enabling them to reach their full potential. »
© 2025 Biopharma Boardroom. All Rights Reserved.